Published in Cancer Cell on June 02, 2009
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
The Hippo pathway: regulators and regulations. Genes Dev (2013) 4.55
NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol (2010) 2.77
A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun (2014) 2.25
NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer (2009) 2.18
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol (2011) 1.87
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol (2010) 1.73
Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol (2011) 1.37
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol (2013) 1.30
ATX-LPA receptor axis in inflammation and cancer. Cell Cycle (2009) 1.27
Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer (2010) 1.25
Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst (2012) 1.24
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther (2010) 1.21
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Detection of gene pathways with predictive power for breast cancer prognosis. BMC Bioinformatics (2010) 1.12
Mechanisms linking obesity and cancer. Biochim Biophys Acta (2013) 1.12
Chemical evolution of autotaxin inhibitors. Chem Rev (2012) 1.12
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One (2010) 1.12
NFAT promotes carcinoma invasive migration through glypican-6. Biochem J (2011) 1.09
Real-time motion analysis reveals cell directionality as an indicator of breast cancer progression. PLoS One (2013) 1.08
Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer (2010) 1.08
Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med (2012) 1.07
Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci (2013) 1.07
Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys Acta (2012) 1.04
A new hypothesis for the cancer mechanism. Cancer Metastasis Rev (2012) 1.03
Stat3 mediates expression of autotaxin in breast cancer. PLoS One (2011) 1.03
GPCRs and cancer. Acta Pharmacol Sin (2012) 1.02
Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci (2013) 1.02
Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans (2012) 1.01
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res (2010) 1.01
TNFAIP8: a new effector for Galpha(i) coupling to reduce cell death and induce cell transformation. J Cell Physiol (2010) 1.00
A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res (2014) 0.97
The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine. Am J Physiol Gastrointest Liver Physiol (2010) 0.97
Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem (2011) 0.95
β-Arrestin2 regulates lysophosphatidic acid-induced human breast tumor cell migration and invasion via Rap1 and IQGAP1. PLoS One (2013) 0.95
Lysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway. Blood (2011) 0.94
Understanding tumor heterogeneity as functional compartments--superorganisms revisited. J Transl Med (2011) 0.93
Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors. Cancer Res (2010) 0.92
Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene (2011) 0.92
Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. Cell Biosci (2013) 0.91
LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS One (2011) 0.91
Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res (2012) 0.90
Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta (2014) 0.89
LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol (2011) 0.88
Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. Blood (2014) 0.87
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. Prostate (2011) 0.87
CARMA3: A novel scaffold protein in regulation of NF-κB activation and diseases. World J Biol Chem (2010) 0.86
Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. J Biol Chem (2012) 0.86
Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One (2013) 0.86
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol (2012) 0.85
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS One (2011) 0.85
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol (2011) 0.85
Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice. J Lipid Res (2014) 0.85
LSD1 controls metastasis of androgen-independent prostate cancer cells through PXN and LPAR6. Oncogenesis (2014) 0.85
Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. Nat Struct Mol Biol (2011) 0.85
Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget (2015) 0.84
Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett (2010) 0.84
Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. J Lipid Res (2015) 0.83
Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J (2013) 0.83
Colorectal cancer cells - Proliferation, survival and invasion by lysophosphatidic acid. Int J Biochem Cell Biol (2010) 0.83
Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke. J Biol Chem (2013) 0.82
Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases. J Biol Chem (2016) 0.82
Mammary tumorigenesis through LPA receptor signaling. Cancer Cell (2009) 0.82
Autotaxin downregulates LPS-induced microglia activation and pro-inflammatory cytokines production. J Cell Biochem (2014) 0.82
The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget (2015) 0.82
Gene expression of the lysophosphatidic acid receptor 1 is a target of transforming growth factor beta. Oncogene (2012) 0.81
Exocrine pancreatic carcinogenesis and autotaxin expression. PLoS One (2012) 0.81
A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Res (2015) 0.81
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget (2014) 0.81
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. Cancer J (2013) 0.81
Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin Cancer Res (2013) 0.81
A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. Cancer Inform (2014) 0.81
Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget (2016) 0.81
Effects of lysophospholipids on tumor microenvironment. Cancer Microenviron (2011) 0.80
Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. J Lipid Res (2015) 0.80
LPA stimulates intestinal DRA gene transcription via LPA2 receptor, PI3K/AKT, and c-Fos-dependent pathway. Am J Physiol Gastrointest Liver Physiol (2011) 0.80
Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One (2014) 0.80
Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis. Mol Cancer (2011) 0.80
Autotaxin: its role in biology of melanoma cells and as a pharmacological target. Enzyme Res (2011) 0.79
Krüppel-like factor 5 incorporates into the β-catenin/TCF complex in response to LPA in colon cancer cells. Cell Signal (2015) 0.79
Metabolic Signatures of Human Breast Cancer. Mol Cell Oncol (2015) 0.79
Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response. J Immunol (2014) 0.79
Lysophosphatidic Acid Up-Regulates Hexokinase II and Glycolysis to Promote Proliferation of Ovarian Cancer Cells. Neoplasia (2015) 0.78
TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation. Cell Discov (2016) 0.78
Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines. Front Oncol (2013) 0.78
The polybasic insertion in autotaxin α confers specific binding to heparin and cell surface heparan sulfate proteoglycans. J Biol Chem (2012) 0.78
Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate. PLoS One (2013) 0.78
Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo. J Biomed Res (2015) 0.77
The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life. PLoS One (2015) 0.77
Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. PLoS One (2012) 0.77
Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers. Clin Exp Med (2014) 0.77
Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade. Arthritis Res Ther (2014) 0.76
Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis. PLoS One (2013) 0.76
Eicosopentaneoic Acid and Other Free Fatty Acid Receptor Agonists Inhibit Lysophosphatidic Acid- and Epidermal Growth Factor-Induced Proliferation of Human Breast Cancer Cells. J Clin Med (2016) 0.76
Expression and regulation of Enpp2 in rat uterus during the estrous cycle. J Vet Sci (2011) 0.76
Tetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate. J Lipid Res (2016) 0.76
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
p53 mutations in human cancers. Science (1991) 31.96
Stat3 as an oncogene. Cell (1999) 17.39
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell (1987) 5.57
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell (1989) 4.88
An atomic model of the interferon-beta enhanceosome. Cell (2007) 4.22
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
The ins and outs of lysophosphatidic acid signaling. Bioessays (2004) 3.62
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 3.24
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Living with p53, dying of p53. Cell (2007) 2.62
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res (2007) 2.04
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res (2003) 1.83
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78
Lysophospholipids activate ovarian and breast cancer cells. Biochem J (1995) 1.76
G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A (2005) 1.75
Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol (2001) 1.73
Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem (2007) 1.69
The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol (1994) 1.67
Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci (2000) 1.67
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A (2006) 1.61
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem (2006) 1.61
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today (2006) 1.48
RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle (2007) 1.45
Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol (2003) 1.36
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther (2007) 1.29
Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res (2004) 1.29
LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol (2007) 1.28
Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med (2007) 1.24
Abnormal serum lysophospholipids in multiple myeloma patients. Lipids (1999) 1.19
Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta (2007) 1.18
In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene (2008) 1.17
Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem (2004) 1.17
Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene (1999) 1.14
Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res (2007) 1.11
Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol Cancer Res (2007) 1.09
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem (2004) 1.09
Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene (2005) 1.07
Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J Biol Chem (2004) 0.96
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. J Biol Chem (2008) 0.95
Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A (2008) 0.90
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol (2007) 0.88
Inducible expression of FGF-3 in mouse mammary gland. Proc Natl Acad Sci U S A (2002) 0.81
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
A custom microarray platform for analysis of microRNA gene expression. Nat Methods (2004) 9.44
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med (2003) 4.69
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst (2005) 4.25
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13
A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res (2008) 4.06
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85
Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell (2007) 3.84